Xin Lang Cai Jing·2025-12-26 06:18Core Viewpoint - Shanghai Haohai Biological Technology Co., Ltd. announced that its actual controller, Mr. Jiang Wei, received regulatory penalties for personal actions in the securities market, which has drawn market attention [1][4]. Group 1: Regulatory Actions - Mr. Jiang Wei was penalized by the China Securities Regulatory Commission for insider trading and advising others to trade securities, with the investigation process taking several months from the initial notice to the final decision [1][4]. - The company clarified that the penalties are directed at Mr. Jiang personally and are unrelated to the operations of Haohai Biological, emphasizing that he does not participate in daily management [1][4]. Group 2: Company Operations and Governance - Despite the personal nature of the incident, it has prompted scrutiny of the company's governance structure and future development, as Haohai Biological is a well-known entity in the biomedical materials sector and the first pharmaceutical company listed on both the Hong Kong Stock Exchange and the STAR Market [2][5]. - The long-term value of the company is contingent upon the development potential of its core business and market competitiveness, particularly in the fields of medical aesthetics and ophthalmology, which are recognized for their growth prospects but also face challenges such as industry competition and market demand fluctuations [2][5][6]. - The management's focus should be on maintaining stable operations while driving technological innovation and strengthening market position to gain long-term trust from the capital market, which is more critical than addressing a single incident [2][6].